Ribociclib – Targeted CDK4/6 Inhibitor Breast Cancer Therapy
Ribociclib is a systemic antineoplastic agent formulated as a highly selective small-molecule inhibitor of cyclin-dependent kinases types 4 and 6 (CDK4/6). The mechanism of action of ribociclib targets and suppresses the enzymatic activity of CDK4/6 complexes bound to cyclin D1, which play a fundamental role in cell cycle regulation. Blockade of these kinase complexes effectively prevents the phosphorylation of the retinoblastoma (pRb) protein. Maintaining pRb in its unphosphorylated state keeps the E2F transcription factor bound and inactive, thereby halting cell cycle progression from the G1 phase into the S phase of DNA synthesis. This process suppresses the uncontrolled proliferation of tumor cells and induces cellular senescence in hormone-receptor-positive breast cancer lines. Ribociclib exhibits a prominent synergistic effect when co-administered with aromatase inhibitors or fulvestrant, preventing estrogen receptor reactivation and overcoming endocrine therapy resistance pathways.
The clinical uniqueness of ribociclib lies in its established ability to significantly prolong progression-free survival (PFS) and overall survival (OS) in women presenting with advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This therapeutic efficacy extends to postmenopausal women as well as pre- and perimenopausal patients when combined with gonadotropin-releasing hormone agonists. Following oral administration, ribociclib is rapidly absorbed, reaching peak plasma concentrations within 1 to 4 hours. Systemic bioavailability is unaffected by food intake. Human plasma protein binding is approximately 70%. The drug undergoes intensive hepatic biotransformation, primarily mediated by the CYP3A4 isoenzyme, yielding multiple inactive or low-activity metabolites. The elimination half-life is approximately 32 hours, allowing for a convenient once-daily dosing schedule. Systemic clearance occurs predominantly through the feces (69%) and partially via the kidneys (23%) as metabolites and unchanged drug.
The drug is administered orally according to an intermittent dosing schedule. Initiating therapy mandates regular laboratory monitoring of complete blood counts to manage neutropenia risks. Strict monitoring of liver function (including ALT, AST, and bilirubin levels) and routine ECG tracking of the QT interval are also mandatory prior to treatment initiation, during the initial cycles, and as clinically indicated due to risks of QT prolongation.
Indications
Ribociclib is indicated for the systemic targeted endocrine therapy of adult patients presenting with the following oncological malignancies:
- Metastatic Breast Cancer (MBC): management of locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.
- Advanced Hormone-Dependent Breast Cancer: treatment of advanced HR+ and HER2-negative metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy, or as first-line treatment.
- Pre/Perimenopausal Cohort Therapy: in pre- or perimenopausal women, the endocrine-based therapy combined with ribociclib must be concurrently administered with a gonadotropin-releasing hormone (GnRH) agonist to achieve ovarian function suppression.
Dosage and administration
The dosing regimen of ribociclib is customized based on a standard intermittent schedule, requiring careful monitoring of individual patient safety and tolerability profiles.
- Standard Daily Dose: the recommended initial dose is 600 mg (three 200 mg tablets) taken orally once daily. The drug is administered daily for 21 consecutive days, followed by a mandatory 7-day treatment break, completing a full 28-day treatment cycle.
- Administration Method: tablets must be swallowed whole with a glass of water and must not be chewed, crushed, or split prior to swallowing. The drug can be taken with or without food, but must be administered at approximately the same time each day (preferably in the morning). Co-administration with grapefruit or grapefruit juice is strictly prohibited.
- Missed Dose and Vomiting: if the patient experiences vomiting after capsule ingestion or if a dose is missed, an additional tablet must not be taken that day. The regular dosing schedule must be resumed the following day at the usual planned time.
- Dose Modifications for Toxicity: in the event of severe neutropenia, pronounced elevations in liver transaminases (ALT/AST), or QT interval prolongation exceeding 480–500 ms, the daily dose should be down-titrated in steps from 600 mg to 400 mg daily, and down to 200 mg daily if required, or temporarily interrupted or permanently discontinued.
- Duration of Therapy: ribociclib treatment should be maintained continuously as long as clinical benefit is observed or until the development of unacceptable systemic toxicity.
